The role of lower dose steroid therapy with vitamin D replacement in patients with idiopathic granulomatous mastitis
Clinic of General Surgery, İstanbul Health Science University Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Türkiye
Abstract
Objective: Low-dose steroid therapy has been recommended in idiopathic granulomatous mastitis (IGM) in various studies in the literature, but the therapeutic minimum dose has not been determined yet. Furthermore, vitamin D deficiency, the effect of which is accepted in autoimmune diseases, has not been previously examined in IGM. The aim of our study was to evaluate the efficacy of lower dose steroid theraphy with adjustment of vitamin D replacement doses with measuring serum 25-hydroxyvitamin D levels in patients with idiopathic granulomatous mastitis (IGM).
Material and Methods: Vitamin D levels were evaluated in 30 IGM patients who applied to our clinic between 2017-2019. Vitamin D replacement was performed in patients with serum 25-hydroxyvitamin D level below 30 ng/mL and prednisolone was given to all patients at a dose of 0.05-0.1 mg/kg/ day. Clinical recovery times of the patients were compared with the literature.
Results: Vitamin D replacement was given to 22 (73.33%) patients. Recovery time was shorter in patients receiving vitamin D replacement (7.62 ± 2.38; 9.00 ± 3.38; p= 0.680). Average recovery time was 8.00 ± 2.68 weeks.
Conclusion: Treatment of IGM can be carried out with lower dose steroid therapy, leading to less complications and lower costs. Measuring serum 25-hydroxyvitamin D level and treating it with the appropriate dose may contribute to the healing process.
Keywords: Idiopathic granulomatous mastitis, lower doses of steroid theraphy, vitamin D
Cite this article as: Altıntaş T. The role of lower dose steroid therapy with vitamin D replacement in patients with idiopathic granulomatous mastitis. Turk J Surg 2022; 38 (3): 250-254.
The approval for this study was obtained from İstanbul Health Science University Kanuni Sultan Süleyman Training and Research Hospital Clinical Research Ethics Committee (Decision no: 236, Date: 11.08.2021).
Externally peer-reviewed.
Concept - T.A.; Design - T.A.; Supervision - T.A.; Fundings - T.A.; Materials - T.A.; Data Collection and/or Processing - T.A.; Analysis and/or Interpretation - T.A.; Literature Search - T.A.; Writing Manuscript - T.A.; Critival Review - T.A.;
The authors have no conflicts of interest to declare.
The authors declared that this study has received no financial support.